Article

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.

Division of Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada.
Blood (impact factor: 9.9). 04/2009; 114(3):522-5. DOI:10.1182/blood-2008-12-193458 pp.522-5
Source: PubMed

ABSTRACT Although the combination of lenalidomide and dexamethasone is effective therapy for patients with relapsed/refractory multiple myeloma, the influence of high-risk cytogenetic abnormalities on outcomes is unknown. This subanalysis of a large, open-label study investigated the effects of the most common unfavorable cytogenetic abnormalities detected by fluorescence in situ hybridization, del(13q), t(4;14), and del(17p13), in 130 evaluable patients treated with this regimen. Whereas patients with either del(13q) or t(4;14) experienced a median time to progression and overall survival comparable with those without these cytogenetic abnormalities, patients with del(17p13) had a significantly worse outcome, with a median time to progression of 2.22 months (hazard ratio, 2.82; P < .001) and median overall survival of 4.67 months (hazard ratio, 3.23; P < .001). Improved therapeutic strategies are required for this subgroup of patients. This study was registered at www.ClinicalTrials.gov as #NCT00179647.

0 0
 · 
0 Bookmarks
 · 
33 Views
  • Source
    Article: Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma.
    Johann Micallef, Moyez Dharsee, Jian Chen, Suzanne Ackloo, Ken Evans, Luqui Qiu, Hong Chang
    [show abstract] [hide abstract]
    ABSTRACT: Multiple myeloma (MM) is the second most common hematological malignancy in adults. It is characterized by clonal proliferation of terminally differentiated B lymphocytes and over-production of monoclonal immunoglobulins. Recurrent genomic aberrations have been identified to contribute to the aggressiveness of this cancer. Despite a wealth of knowledge describing the molecular biology of MM as well as significant advances in therapeutics, this disease remains fatal. The identification of biomarkers, especially through the use of mass spectrometry, however, holds great promise to increasing our understanding of this disease. In particular, novel biomarkers will help in the diagnosis, prognosis and therapeutic stratification of MM. To date, results from mass spectrometry studies of MM have provided valuable information with regards to MM diagnosis and response to therapy. In addition, mass spectrometry was employed to study relevant signaling pathways activated in MM. This review will focus on how mass spectrometry has been applied to increase our understanding of MM.
    Journal of Hematology & Oncology 04/2010; 3:13. · 3.99 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

130 evaluable patients
 
common unfavorable cytogenetic abnormalities
 
cytogenetic abnormalities
 
hazard ratio
 
high-risk cytogenetic abnormalities
 
lenalidomide
 
median time
 
open-label study
 
patients
 
relapsed/refractory multiple myeloma
 
situ hybridization
 
subanalysis
 
subgroup
 
survival comparable
 
worse outcome